OKYO Pharma Limited announced the enrollment of its first patients in the Phase 3 NEPTUNE pivotal clinical trial evaluating urcosimod for neuropathic corneal pain (NCP). The multicenter study, initiated at Toyos Clinic in Nashville by Dr. Melissa Toyos, will expand to sites across the U.S., Italy, Spain, and France. Patients receive four drops daily for 12 weeks, with the primary efficacy endpoint measuring changes in ocular pain via VAS scores. This milestone advances clinical evidence for urcosimod as a potential first-in-class treatment for an unmet medical need. OKYO Pharma is a clinical-stage biopharmaceutical company developing therapies for neuropathic corneal pain and anterior segment eye diseases.
